Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

localized scleroderma - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

localized scleroderma

MONDO:0019562

Also known as:Scleroderma, circumscribed or localisedScleroderma, circumscribed or localizedcircumscribed scleroderma

Find Clinical TrialsTrials

Overview

Localized scleroderma is the skin localized form of scleroderma characterized by fibrosis of the skin causing cutaneous plaques or strips.

TreatmentsNo approved treatments · 2 in pipeline

Clinical Trials7 registered · 4 recruiting

Diagnosis

Biomarker and diagnostic research for localized scleroderma has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for localized scleroderma. An additional 2 compounds hold orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for localized scleroderma, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for localized scleroderma. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Prognosis

Estimated prevalence: 1-9 in 100,000 (Uncommon).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

7 clinical trials registered, 4 recruiting. Interventions under study include other interventions, medical devices, and procedural interventions. Pipeline includes 3 NA. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT01808937](https://clinicaltrials.gov/study/NCT01808937)

Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 10:03 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:90289

GARD

Genetic and Rare Diseases Info Center

GARD:7058

Questions for Your Care Team

→Are any of the 7 active clinical trials a good fit for my situation?
→What is the current development status of HDF-LV-RTS-MMP1 (human dermal fibroblasts genetically modified with LV-RTS-MMP1) and Veledimex, and when might it become available?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	48	31%
Research summaries	37	24%
Laboratory research	16	10%
Disease patterns and progression	15	10%
Other research	14	9%
Testing and diagnosis research	10	6%
Clinical study results	10	6%
New treatment approaches	6	4%

Kisho

localized scleroderma

Overview

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Navigating the Unknown: Scleroderma Renal Crisis and a Fatal Cardiac Complication in a Young Patient With MCTD With Coexisting Anti-U3 RNP and Anti-RNA Polymerase III Antibodies.

Scleroderma Renal Crisis in Mixed Connective Tissue Disease.

Cellular and molecular dysregulation of the esophageal epithelium in systemic sclerosis.

localized scleroderma

Overview

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Navigating the Unknown: Scleroderma Renal Crisis and a Fatal Cardiac Complication in a Young Patient With MCTD With Coexisting Anti-U3 RNP and Anti-RNA Polymerase III Antibodies.

Scleroderma Renal Crisis in Mixed Connective Tissue Disease.

Cellular and molecular dysregulation of the esophageal epithelium in systemic sclerosis.